OTLK
Income statement / Annual
Last year (2023), Outlook Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Outlook Therapeutics, Inc.'s net income was -$58.98 M.
See Outlook Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
09/30/2023 |
09/30/2022 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
09/30/2015 |
09/30/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$8.15 M
|
$3.09 M
|
$3.81 M
|
$2.98 M
|
$5.22 M
|
$9.05 M
|
| Cost of Revenue |
$44,188.00 |
$204,694.00 |
$262,139.00 |
$554,069.00 |
$23,805.00 |
$18,504.00 |
$23,809.00 |
$32,763.00 |
$38,876.00 |
$14,124.00 |
| Gross Profit |
-$44,188.00 |
-$204,694.00 |
-$262,139.00 |
-$554,069.00 |
$8.12 M |
$3.07 M |
$3.79 M |
$2.95 M |
$5.18 M |
$9.04 M |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
1 |
0.99 |
0.99 |
0.99 |
0.99 |
1 |
| Research and Development
Expenses |
$26.45 M
|
$42.33 M
|
$38.96 M
|
$26.34 M
|
$23.81 M
|
$18.50 M
|
$23.81 M
|
$32.76 M
|
$38.88 M
|
$14.12 M
|
| General & Administrative
Expenses |
$26.67 M
|
$20.74 M
|
$12.77 M
|
$9.97 M
|
$9.37 M
|
$14.23 M
|
$15.88 M
|
$21.64 M
|
$12.91 M
|
$7.32 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$279,675.00
|
-$1.90 M
|
-$3.85 M
|
-$7.25 M
|
-$2.69 M
|
-$2.47 M
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$26.67 M
|
$20.74 M
|
$13.05 M
|
$8.08 M
|
$5.52 M
|
$6.97 M
|
$13.19 M
|
$19.17 M
|
$12.91 M
|
$7.32 M
|
| Other Expenses |
-$3.76 M |
-$882,903.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$53.13 M |
$63.07 M |
$51.73 M |
$36.31 M |
$29.33 M |
$25.48 M |
$39.69 M |
$51.93 M |
$51.78 M |
$21.44 M |
| Cost And Expenses |
$53.13 M |
$63.07 M |
$51.73 M |
$36.31 M |
$32.69 M |
$28.53 M |
$39.69 M |
$54.74 M |
$51.78 M |
$21.44 M |
| Interest Income |
$1,559.75 |
$1,487.46 |
$936.13 |
$1,756.47 |
$3,466.69 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$1.56 M |
$1.49 M |
$936,000.00 |
$1.76 M |
$3.47 M |
$3.89 M |
$5.63 M |
$1.47 M |
$2.30 M |
$901,052.00 |
| Depreciation &
Amortization |
$44,188.00
|
$204,694.00
|
$262,139.00
|
$554,069.00
|
$3.36 M
|
$3.05 M
|
$2.69 M
|
$2.39 M
|
$1.82 M
|
$878,477.00
|
| EBITDA |
-$52.60 M
|
-$62.91 M
|
-$51.77 M
|
-$36.31 M
|
-$21.67 M
|
-$22.39 M
|
-$33.19 M
|
-$49.36 M
|
-$44.74 M
|
-$11.51 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
-2.66 |
-7.25 |
-8.71 |
-16.57 |
-8.57 |
-1.27 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
-4.46
|
-8.24
|
-9.41
|
-17.37
|
-8.92
|
-1.37
|
| Total Other
Income/Expenses Net |
-$4.29 M
|
-$2.98 M
|
-$1.43 M
|
-$1.67 M
|
-$1.64 M
|
-$8.30 M
|
$3.16 M
|
-$1.47 M
|
-$2.30 M
|
-$901,052.00
|
| Income Before Tax |
-$58.98 M |
-$66.05 M |
-$53.16 M |
-$38.51 M |
-$37.93 M |
-$33.74 M |
-$38.35 M |
-$53.23 M |
-$48.86 M |
-$13.29 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
-4.66
|
-10.93
|
-10.06
|
-17.86
|
-9.36
|
-1.47
|
| Income Tax Expense |
$3,000.00 |
$2,800.00 |
$2,000.00 |
-$3.27 M |
-$3.41 M |
-$3.65 M |
$501,500.00 |
$103,000.00 |
-$190,111.00 |
$439,018.00 |
| Net Income |
-$58.98 M |
-$66.05 M |
-$53.16 M |
-$35.24 M |
-$34.52 M |
-$46.11 M |
-$38.85 M |
-$53.33 M |
-$47.39 M |
-$13.73 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
-4.24 |
-14.94 |
-10.19 |
-17.9 |
-9.08 |
-1.52 |
| EPS |
-4.72 |
-6.23 |
-6.96 |
-9.71 |
-37.96 |
-50.7 |
-258.75 |
-495.71 |
-504.47 |
-155.35 |
| EPS Diluted |
-4.72 |
-6.23 |
-6.96 |
-9.71 |
-37.96 |
-50.7 |
-258.54 |
-495.71 |
-504.47 |
-155.35 |
| Weighted Average Shares
Out |
$12.51 M
|
$10.60 M
|
$7.63 M
|
$3.63 M
|
$909,591.00
|
$909,591.00
|
$150,139.00
|
$107,581.00
|
$93,946.00
|
$88,398.00
|
| Weighted Average Shares
Out Diluted |
$12.51 M
|
$10.60 M
|
$7.63 M
|
$3.63 M
|
$909,591.00
|
$909,591.00
|
$150,261.00
|
$107,581.00
|
$93,946.00
|
$88,398.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
